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Abstract
Background: There exist several reports of atopy and allergen-specific IgE-mediated hypersensitivity transferred by
bone marrow transplantation, and it has been concluded that the transfer of allergic reactivity results from adoptive
transfer of IgE-producing donor-derived B- and/or plasma cells. To the best of our knowledge we report the first
case of peanut allergy after PBSCT.
Case Presentation: A 55-year-old anciently non allergic man with secondary acute myeloid leukemia (AML)
received an allogeneic peripheral blood stem cell transplantation from a matched unrelated donor following
reduced-intensity conditioning. On day 32 after PBSCT, while still on prophylactic systemic immunosuppression, the
patient noticed a first episode of angioedema with swelling of the nasal and oral mucosa 30 min after consuming
peanut puffs. In a second episode, eight months after PBSCT, he again developed angioedema, generalized pruritus
and nausea within minutes after eating biscuits containing hazelnut and peanut. Moreover, after topical application
of a peanut oil-containing ointment, the patient experienced facial erythema and angioedema. Nine months after
PBSCT an evaluation for peanut allergy revealed a highly increased specific IgE to peanut of 75.9 kU/l. Accordingly,
skin prick tests for peanut extract were also positive. In consequence, the patient was counseled to strictly avoid
peanut-related products, and provided with an emergency set. No adverse allergic events have occurred since for
an observation time of 15 months after PBSCT. The stem cell donor was contacted and confirmed intolerance to
peanuts. His specific serum IgE pattern nine month after PBSCT harvest was analysed and showed similar
sensitization profiles compared to those of the transplant recipient.
Conclusions: Because of the close temporal association between the onset of allergic symptoms in the PBSC
recipient it is reasonable to assume that the acquired peanut allergy had been transferred from the donor to the
recipient by the PBSC graft.
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Background
Atopy and food sensitization following solid-organ or
bone marrow transplantation has previously been re-
ported [1–6]. One theorised mechanism is the
sensitization by passive transfer of donor IgE [7]. An-
other concept is the allergy transfer via mature specific
T and/or B lymphocytes leading to active production of
allergen-spezific IgE in the transplant recipient [1, 2].
The relevance of the immunosuppressive therapy (par-
ticularly of tacrolimus) for post-transplant allergies has
also been previously discussed [8, 9].
Here, we present the case of a male patient who unex-
pectedly developed anaphylactic peanut allergy after he
received peripheral blood stem cell transplantation
(PBSCT) for acute myeloid leukaemia.
Case presentation
A 55-year-old male patient who received peripheral
blood stem cell transplantation (PBSCT) for acute
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myeloid leukaemia unexpectedly developed anaphylactic
peanut allergy.
In his past medical history, the index patient had not
experienced any allergic food reactions or atopy, and in
particular he had regularly ingested peanut products
without any problems. There was no atopic dermatitis,
asthma or pollinosis in the family. The patient’s further
medical history included a colon adenocarcinoma stage
II treated by hemicolectomy followed by adjuvant
chemotherapy in 2002 and partial nephrectomy for renal
cell carcinoma stage 1a in 2006. In 2010, the diagnosis
of secondary acute myeloid leukemia (AML) with
NPM1-mutation and normal karyotype was established,
and he received intensive induction and consolidation
chemotherapy with AraC and anthracyclin-based regi-
mens. In 2011, his AML relapsed. After achieving a sec-
ond remission by salvage chemotherapy, the patient
received an allogeneic peripheral blood stem cell trans-
plantation from a matched unrelated donor following
reduced-intensity conditioning. Immunosuppression for
the prevention of graft-versus-host disease (GvHD) com-
prised pre-transplant antithymoglobulin (ATG), as well
as cyclosporine (CsA) from day 0 through 120 and my-
cophenolate mofetil (MMF) from day 0 through 28.
Hematological engraftment occurred on day 10, with
complete donor chimerism in the peripheral blood
achieved from day 14 on. Immune reconstitution mir-
rored by CD4-T-cell counts >200/μl were documented
from day 120 on. The patient then developed extensive
chronic GvHD of the skin, necessitating local and sys-
temic steroids as well as tacrolimus at trough levels (5–
10 ng/ml) starting at 6 months after transplantation.
On day 32 after PBSCT, while still on prophylactic sys-
temic immunosuppression and receiving an otherwise
defined low-bacteria lactose-free diet, the patient noticed
a first episode of angioedema with swelling of the nasal
and oral mucosa 30 min after consuming peanut puffs.
In a second episode, eight months after PBSCT while on
normal nutrition, he again developed angioedema, gen-
eralized pruritus and nausea within minutes after eating
biscuits containing hazelnut and peanut. There have
been no cardiovascular symptoms. The patient was suc-
cessfully treated intravenous with 250 mg methylpred-
nisolone and 2 mg clemastine.
Moreover, between 2nd and 4th week after PBSCT
occasional topical application of a refined peanut oil-
containing lipid replenishing cream induced skin ery-
thema and pruritus within minutes.
These events prompted an evaluation for peanut al-
lergy nine months after PBSCT, revealing a total IgE of
202 kU/l and a highly increased specific IgE to peanut of
75.9 kU/l. In detail, we found high specific IgE to the
major recombinant peanut allergens Ara h1, Ara h2 and
Ara h3 (Table 1). Accordingly, skin prick tests for peanut
extract were also positive (>6 mm). In consequence, the
patient was counseled to strictly avoid peanut-related
products, and provided with an emergency set (contain-
ing self-injectable epinephrine, liquid oral antihistamines
and steroid). The patient strictly avoided further expos-
ition to peanut products, and no further adverse allergic
events occurred. Unfortunately, the patient succumbed
to progressive leukemia 36 months after PBSCT.
The stem cell donor was contacted and confirmed
clinical allergy to peanuts and negated any other aller-
gies. His specific serum IgE pattern nine month after
PBSCT harvest was analysed and showed similar
sensitization profiles compared to those of the transplant
recipient with increased specific IgE to peanut and high
specific IgE to the major recombinant peanut allergens
Ara h1, Ara h2 and Ara h3 (Table 1).
Although the sensitization profiles of donor and re-
cipient (reactions against Ara h1, Ara h2 and Ara h3)
can be found in a large proportion of true peanut aller-
gic patients it is reasonable to assume that the acquired
peanut allergy had been transferred from the donor to
the recipient by the PBSC graft.
There exist several reports of atopy and allergen-
specific IgE-mediated hypersensitivity other than peanut
transferred by bone marrow transplantation, and it has
been concluded that the transfer of allergic reactivity re-
sults from adoptive transfer of IgE-producing donor-
derived B- and/or plasma cells [1, 2]. The case of the
index patient presented here is compatible with this con-
cept of allergy transfer via mature specific memory B-
cells, eliciting a reactivity pattern almost identical to that
of the donor. To the best of our knowledge it is the first
case of peanut allergy after PBSCT. Numbers of trans-
planted cells were generally higher in PBSC than BM
grafts (e. g. G-CSF-primed peripheral blood grafts con-
tain approximately 10-fold more T-cells) and are associ-
ated with better engraftment but increased risk of
(chronic) GvHD. The mature specific memory B-cells in
Table 1 Specific IgE and skin prick test in the transplant
recipient and the transplant donor
Test Allergen Results 9 months after PBSCT
Transplant recipient Transplant donor
sIgE Total IgE 202 kU/l 361 kU/l
Peanut 75.9 kU/l >100 kU/l
rArah1 7.02 kU/l 45.3 kU/l
rArah2 7.73 kU/l 30.9 kU/l
rArah3 36.50 kU/l 31.70 kU/l
rArah8 <0.35 kU/l 0.68 kU/l
rArah9 <0.35 kU/l <0.35 kU/l
Skin prick test Peanut (1:10) ++++ (>6 mm) Not performed
sIgE serum IgE, PBSCT peripheral blood stem cell transplantation
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the index patient must have been either circulating
blood B-cells or they had been mobilized from the mar-
row into the blood by the G-CSF pre-treatment of the
PBSC donor. An additional pro-allergenic influence of
progenitor cell mobilization with G-CSF is conceivable.
In addition to the late reaction to peanut products at-
tributable to the engraftment of specific B-cells, the
index patient had also experienced mild reactions to
peanut products between 2nd and 4th week after trans-
plantation. While assuming that this reaction already
was a symptom of the peanut reactivity, it appears un-
likely that the B-cells transferred with the graft might
have produced the amounts of IgE responsible for the
reaction at that early time point. Yet, because the graft
had been transplanted in a volume of 300 ml, it is con-
ceivable that passive transfer of IgE itself in the PBSC-
bag or of cell-bound IgE contributed to the reaction.
Such passive and transient transfer of peanut allergy has
been described in solid-organ transplants for patients
having received liver [3], lung [4], combined liver-kidney
transplants [5] or combined pancreas-kidney transplants
[6]. While the transfer of IgE-mediated allergy in BMT
can be explained by the transfer of long-living plasma
cells in the bone marrow [10], solid organs such as the
lungs have not been described to harbor such long-living
plasma cells. Alternatively, IgE itself has been described
a carrier of IgE-mediated memory [7] and might there-
fore be responsible for persisting allergic reactions.
The relevance of the immunosuppressive therapy with
CsA, MMF and tacrolimus for post-transplant allergies
was previously discussed. In particular tacrolimus seems
to be a potential risk factor, as it may lead to a Th1/Th2
imbalance towards Th2 and also inhibited the regulatory
T cells by suppression of interleukin 2 [8, 9]. Thus in our
case an additional effect of tacrolimus on the occurrence
of posttransplant peanut sensitization appears conceivable.
Especially in patients with altered skin barrier function the
cutaneous exposure to food protein can induce allergic
sensitization [11]. Refined topical peanut oil products as
applied by our patient are considered to be safe and the
risk to induce type I allergy very low [12]. However an
additional effect with sensitization via the peanut contain-
ing ointment is therefore unlikely in our case in our opin-
ion, but might principally also be possible.
Conclusion
This case documents a probable stable transfer of IgE-
memory cells by peripheral stem cell transplantation,
which elicitied significant clinical symptoms. Although
uncommon, the consequences of transplant-conveyed al-
lergies can be life-threateningly severe. Thus, exclusion
of significant type-I allergies prior to performing PBSCT
appears to be a worthwhile investment. In case of known
hypersensitivity in the donor, we recommend adequate
testing and counselling of the PBSC recipient.
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